Novel agents and new therapeutics in castration-resistant prostate cancer

Current Opinion in Oncology

Volumn 23, Issue 3, 2011, Pages 290-296

  Wu, Yichao ^a   Rosenberg, Jonathan E ^a   Taplin, Mary Ellen ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

abiraterone acetate; cabazitaxel; castration resistant prostate cancer; immunotherapy; intermittent androgen deprivation therapy; MDV3100

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE; ABIRATERONE ACETATE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CABAZITAXEL; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENOSUMAB; DOCETAXEL; IPILIMUMAB; KETOCONAZOLE; MDX 1106; MITOXANTRONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROSTVAC; PROVENGE; STEROID; TAK 700; TOK 001; UNCLASSIFIED DRUG; XL 184; ZOLEDRONIC ACID;

ANDROGEN DEPRIVATION THERAPY; BONE MINERAL; CANCER PREVENTION; CANCER RESISTANCE; CANCER SURVIVAL; CASTRATION; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; FATIGUE; HUMAN; IMMUNOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASTRATION; ENZYME INHIBITORS; HUMANS; MALE; POLY(ADP-RIBOSE) POLYMERASES; PROSTATIC NEOPLASMS; PROTEIN-TYROSINE KINASES;

EID: 79954994034     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3283449400     Document Type: Review

References (45)

1. American Cancer Society. Cancer facts & figures 2009. Atlanta, GA: American Cancer Society, 2009.
2. Moreau JP, Delavault P, Blumberg J. Luteinizing hormone-releasing hormone agonists in the treatment of PCa: a review of their discovery, development, and place in therapy. Clin Ther 2006; 28:1485-1508. (Pubitemid 44841984)
3. Calais da Silva FEC, Bono AV, Whelan P, et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomized phase 3 study of the South European Uroncological Group. Eur Urol 2009; 55:1269-1277.
4. Saad F, Gleason DM, Murray R, et al. A randomised, placebo-controlled trial of zoledronic acid in patients with hormone refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94:1458-1468.
5. Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361:745-755.
6. Fizazi K, Carducci MA, Smith MR, et al. A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol 2010; 28:18s (suppl; abstr LBA4507).
7. Saigal CS, Gore JL, KrupskiTL, et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007; 110:1493-1500. (Pubitemid 47463063)
8. Nguyen PL, Chen MH, Goldhaber SZ, et al. Coronary revascularization and mortality in men with congestive heart failure or prior myocardial infarction who receive androgen deprivation. Cancer 2011; 117:406-413.
9. Taylor LG, Canfield SE, Du XL. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 2009; 115:2388-2399.
10. Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol 2009; 27:92-99.
11. Alibhai SM, Duong-Hua M, Sutradhar R, et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 2009; 27:3452-3458.
12. Locke JA, Guns ES, Lubik AA, et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008; 68:6407-6415.
13. Montgomery RB, Mostaghel EA, Vessel la R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008; 68:4447-4454.
14. Taplin ME, Rajeshkumar B, Halabi S, et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 2003; 21:2673-2678. (Pubitemid 46606310)
15. Waltering KK, Helenius MA, Sahu B, et al. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res 2009; 69:8141-8149.
16. Kawata H, Ishikura N, Watanabe M, et al. Prolonged treatment with bicalu- tamide induces androgen receptor overexpression and androgen hypersen sitivity. Prostate 2010; 70:745-754.
17. Sun S, Sprenger CC, Vessella RL, et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 2010; 120:271 5-2730.
18. Urbanucci A, Waltering KK, Suikki HE, et al. Androgen regulation of the androgen receptor coregulators. BMC Cancer 2008; 8:219-228.
19. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324:787-790.
20. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010; 375:1437-1446.
21. Attard G, Reid AH, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26:4563-4571.
22. Attard G, Reid AH, A'Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009; 27:3742-3748.
23. Ryan CJ, Smith MR, Fong L, et al. Phase I clinical trial of the CYP1 7 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration- resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010; 28:1481-1488.
24. Ryan C, Efstathiou E, Smith M, et al. Phase II multicenter study of chemother apy (chemo)-naive castration-resistant prostate cancer (CRPC) not exposed to ketoconazole (keto), treated with abiraterone acetate (AA) plus prednisone. J Clin Oncol 2009; 27(Suppl.): abstract 5046.
25. Reid AH, Attard G, Danila DC, et al. Significant and sustained antitumor activity in postdocetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010; 28:1489-1495.
26. Danila DC, Morris MJ, de Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel- treated castration-resistant prostate cancer. J Clin Oncol 2010; 28:1496- 1501.
27. Efstathiou E, Tu S, Aparicio A. et al. Use of 'intracrine androgen signaling signature' to predict benefit from abiraterone acetate (AA) in patients with castrate-resistant prostate cancer (CRPC). J Clin Oncol 2010; 28(Suppl.): abstract 4547.
28. de Bono JS, Logothetis C, Fizazi K, et al. Abiraterone acetate plus low dose prednisone improves overall survival in patients with metastatic castration-resistant prostate cancer (CRPC) who have progressed after docetaxel-based chemotherapy: results of COU-AA-201, a randomized double-blind placebo-controlled phase 3 study. Presented at the 2010 European Society for Medical Oncology (ESMO) Annual Meeting, 2010.
29. Dreicer R, Agus DB, MacVicar GR, et al. Safety, pharmacokinetics, and efficacy of TAK-700 in castration-resistant, metastatic prostate cancer: a phase I/II, open-label study. J Clin Oncol 2010; 28:18s (Suppl.; abstract 103).
30. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999; 17:2506-2513. (Pubitemid 29368252)
31. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502-1512. (Pubitemid 39315317)
32. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351:1513-1520. 33 (Pubitemid 39315318)
33. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet 2010; 376: 1147-1154.
34. Kelly WK, Halabi S, Carducci MA, et al. A randomized, double-blind, placebo- controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration- resistant prostate cancer (mCRPC): Survival results of CALGB 90401 .J Clin Oncol 2010; 28:18s (Suppl.; abstract LBA4511).
35. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-422.
36. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with Sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24:3089-3094. (Pubitemid 46638945)
37. Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with Sipuleucel-Tin advanced prostate cancer. Cancer 2009; 115:3670-3679.
38. TM) in patients with prostate cancer. J Transl Med 2006; 4:1-5.
39. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28:1099-1105.
40. Beer TM, Slovin SF, Higano CS, et al. Phase I trial of ipilimumab alone (or in combination with radiotherapy) in patients with metastatic castration resistant prostate cancer. J Clin Oncol 2008; 26(Suppl.):abstract 5004.
41. Fong L, Kwek SS, O'Brien S, et al. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA-4 blockade and GM-CSF. Cancer Res 2009; 69:609-615.
42. +. Prostate 2009; 69:1694-1703.
43. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent antiprogrammed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28:3167-3175.
44. Brahmer JR, Topalian SL, Powderly J, et al. Phase Ib experience with MDX-1106, an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies. J Clin Oncol 2009; 27(Suppl.):abstract 3018.
45. Zhang Y, Guessous F, Kofman A, et al. XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. Drugs 2010; 13:112-121.